“Remission, low disease activity and improvement of pain and function in psoriatic arthritis patients treated with IL-12/23 and IL-17 inhibitors. A multicenter prospective study” (2020) Reumatismo, 72(1), pp. 52–59. doi:10.4081/reumatismo.2020.1266.